[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352212-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352212-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","follow-the-dots-v1-t-cells-as-effectors-of-cancer-immunotherapy","Follow the “DOTs” - Vδ1+ γδ T cells as effectors of cancer immunotherapy","","Cancer immunotherapy has mostly depended on conventional T cells, benefiting only a limited set of tumour types. γδ T cells offer a promising alternative anti-tumour effector pool. The Vδ1+ subset often predominates in peripheral tissues and tumours and correlates with favourable prognosis. This Found in Translation reviews how to harness Vδ1+ γδ T cell biology for cancer immunotherapy, with emphasis on the Delta One T (DOT) cell approach.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/follow-the-dots-v1-t-cells-as-effectors-of-cancer-immunotherapy/352212/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/follow-the-dots-v1-t-cells-as-effectors-of-cancer-immunotherapy/352212.png","ImageObject",300,407,{"name":42,"@type":43},"moss~","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are γδ T cells considered for cancer immunotherapy beyond conventional T cells?","Question",{"text":63,"@type":64},"Conventional T cells have succeeded in only a limited set of tumour types. γδ T cells provide an alternative anti-tumour effector repertoire that can be mobilized for immune intervention.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What features distinguish Vδ1+ γδ T cells in tumours and peripheral tissues?",{"text":68,"@type":64},"Vδ1+ γδ T cells commonly predominate in peripheral tissues and within tumours and are typically associated with good prognosis. They are also described as more resistant to exhaustion than blood Vδ1+ counterparts.",{"name":70,"@type":61,"acceptedAnswer":71},"How do DOT cells relate to Vδ1+ γδ T cell expansion and therapeutic testing?",{"text":72,"@type":64},"A DOT cell protocol uses TCR agonists and cytokines to generate large expansions of blood-derived Vδ1+ γδ T cells within 2–3 weeks. DOT cells have been evaluated across multiple preclinical models and advanced to a first-in-human trial in acute myeloid leukaemia.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352212,1790832169,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Europe PMC unders uthManuscripts Europe M eC und Author Manuscripts  \n| Europe PMC Funders Group\u003Cbr>Author Manuscript\u003Cbr>J Exp Med. Author manuscript; available in PMC 2026 July 10. |\n| --- |\n| Published in final edited form as:\u003Cbr>J Exp Med. ; 223(3): . doi:10.1084/jem.20252289 .\u003Cbr>Follow the “DOTs”: Vδ1+ γδ T cells as effectors of cancer immunotherapy\u003Cbr>Bruno Silva-Santos 1,2,* , Sofia Mensurado 1 , Rafael Blanco-Domínguez 1 , Adrian C. Hayday3,4 1Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal.\u003Cbr>2 Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.\u003Cbr>3King’s College London, London, United Kingdom.\u003Cbr>4The Francis Crick Institute, London, United Kingdom.\u003Cbr>Abstract\u003Cbr>Cancer immunotherapy has mostly relied on conventional T cells to achieve success in a limited set of tumour types. A promising avenue to expand the repertoire of cancers effectively treated through immune intervention is to mobilize other anti-tumour effectors, such as γδ T cells.\u003Cbr>Among these, the Vδ1+ subset commonly predominates within peripheral tissues and within tumours, typically associating with good prognosis. In this Found in Translation, we discuss how to leverage the biological properties of Vδ1+ γδ T cells for cancer immunotherapy, with special focus on the Delta One T (DOT) cell approach.\u003Cbr>Vδ1+ γδ T cells and the “DOT” cell product\u003Cbr>γδ T cells are defined by T cell receptors (TCRs) produced following somatic recombination of genes encoding TCRγ and TCRδ chains. Like antibodies, TCRγδ complexes are rarely restricted by major histocompatibility complex (MHC) / human leukocyte antigen (HLA) and do not recognise processed peptides, unlike conventional □□ TCRs (Hayday et al., 2024). While the identity of antigens for most ofthe TCRγδ repertoire is unelucidated, the dominant γδ T cell population in human peripheral blood, Vγ9Vδ2 T cells, engage a complex of butyrophilins (BTNs) 2A1, 3A1, and (most likely) BTN3A2 where BTN2A1 interacts directly (in the extracellular space) with the Vγ9 TCR chain, and BTN3A1 binds intracellularly to prenyl pyrophosphates (“phosphoantigens”) that accumulate in tumour or infected cells (Mohammed et al., 2025) .\u003Cbr>Although Vγ9Vδ2 T cells clearly display anti-tumour effector functions, namely cytoxicity and production of type 1 cytokines, e.g., interferon (IFN)-γ or tumour necrosis factor (TNF), their clinical translation has been limited by poor expansion in vivo and frequent propensity\u003Cbr>This work is licensed under a CC BY 4.0 International license.\u003Cbr>*Correspondence to B. S.-S. ([bssantos@medicina.ulisboa.pt](bssantos@medicina.ulisboa.pt)) .\u003Cbr>Disclosures\u003Cbr>B. Silva-Santos, S. Mensurado, R. Blanco-Domínguez and A.C. Hayday receive funding from sponsored research agreements with Takeda Development Center Americas, Inc, Lexington, MA, USA. No other disclosures were reported. |\n\nEurope PMC unders uthManuscripts Europe M eC und Author Manuscripts  \nSilva-Santos et al. Page 2  \nto exhaustion (Hayday et al., 2024) . Conversely, we and others have found that their Vδ1+γδ T cell counterparts, which are typically rare in the blood but which predominate in peripheral tissues and within tumours, are more resistant to exhaustion, retaining substantial effector responses to TCR signalling (Correia et al., 2011; Davies et al., 2024) . Moreover, tumour-infiltrating Vδ1+ but not Vδ2+ γδ T cells associated with good prognosis in breast (Wu et al., 2019) and lung (Wu et al., 2022) carcinoma patients; and expanded upon PD-1 immune checkpoint blockade (ICB) in colorectal cancer patients with HLA class I defects (de Vries et al., 2023) . Clearly, these properties make Vδ1+ γδ T cells attractive effectors of cancer immunotherapy.  \nAiming to develop a Vδ1+ γδ T cell-based therapeutic product, we tested thousands of conditions with TCR agonists and cytokines to arrive at the “Delta One T (DOT) cell”  \nprotocol that in 2-3 weeks yields >1,000-fold expansions of blood-derived Vδ1+ γδ T cells, constitu","cbCaivp6rM32bzxt","https://ap.wps.com/l/cbCaivp6rM32bzxt","pdf",605026,"English","# Abstract\n# Vδ1+ γδ T cells and the “DOT” cell product\n## γδ T cell receptor biology and antigen recognition\n## Limits of Vγ9Vδ2 translation and rationale for Vδ1+\n# DOT cells in haematological malignancies\n## B-cell CLL models and therapeutic activity\n## AML models and cytotoxic efficacy","[{\"question\":\"Why are γδ T cells considered for cancer immunotherapy beyond conventional T cells?\",\"answer\":\"Conventional T cells have succeeded in only a limited set of tumour types. γδ T cells provide an alternative anti-tumour effector repertoire that can be mobilized for immune intervention.\"},{\"question\":\"What features distinguish Vδ1+ γδ T cells in tumours and peripheral tissues?\",\"answer\":\"Vδ1+ γδ T cells commonly predominate in peripheral tissues and within tumours and are typically associated with good prognosis. They are also described as more resistant to exhaustion than blood Vδ1+ counterparts.\"},{\"question\":\"How do DOT cells relate to Vδ1+ γδ T cell expansion and therapeutic testing?\",\"answer\":\"A DOT cell protocol uses TCR agonists and cytokines to generate large expansions of blood-derived Vδ1+ γδ T cells within 2–3 weeks. DOT cells have been evaluated across multiple preclinical models and advanced to a first-in-human trial in acute myeloid leukaemia.\"}]","Follow the “DOTs” - Vδ1+ γδ T cells as effectors of cancer immunotherapy | PDF",1790098319,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b59cc693d0e5480c775cfaf938b7430e.webp",983,1272,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bf7b82e5d24ef1c2d4393c60af5e53f.webp",982,1270,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57c214a3a2d479f918cd1acfc5adb3ae.webp",981,1269,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8045f6f2a263b111c484bc5a0c2c332.webp",980,1268]